Omega Therapeutics, Inc. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Collaboration revenue from related party
Operating expenses:
Research and development
General and administrative
Related party expense, net
Total operating expenses
Loss from operations
Other Income (expense), net:
Interest expense, net
Interest income, net
Change in fair value of warrant liability
Other income (expense), net
Total other income, net
Net loss
Net loss per common stock attributable to common stockholders, basic and diluted
Weighted-average common stock used in net loss per share attributable to common stockholders, basic and diluted
Other comprehensive income (loss):
Unrealized gain (loss) on marketable securities
Comprehensive loss
Net loss per common stock attributable to common stockholders, basic
Net loss per common stock attributable to common stockholders, diluted
Weighted-average common stock used in net loss per share attributable to common stockholders, basic
Weighted-average common stock used in net loss per share attributable to common stockholders, diluted

Comments